Blue Trust’s iShares Biotechnology ETF IBB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$218K Buy
1,037
+56
+6% +$11.2K ﹤0.01% 724
2026
Q2
$187K Sell
981
-1
-0.1% -$172 ﹤0.01% 807
2026
Q1
$166K Buy
982
+18
+2% +$3.08K ﹤0.01% 834
2025
Q4
$163K Buy
964
+29
+3% +$4.71K ﹤0.01% 853
2025
Q3
$135K Sell
935
-244
-21% -$33.3K ﹤0.01% 953
2025
Q2
$149K Buy
1,179
+34
+3% +$4.17K ﹤0.01% 879
2025
Q1
$146K Buy
1,145
+57
+5% +$7.73K ﹤0.01% 831
2024
Q4
$144K Buy
1,088
+200
+23% +$28.1K ﹤0.01% 774
2024
Q3
$122K Sell
888
-9
-1% -$1.3K ﹤0.01% 1113
2024
Q2
$123K Hold
897
– – ﹤0.01% 885
2024
Q1
$123K Buy
897
+115
+15% +$15.7K ﹤0.01% 652
2023
Q4
$96K Sell
782
-201
-20% -$24.5K ﹤0.01% 690
2023
Q3
$125K Hold
983
– – ﹤0.01% 558
2023
Q2
$127K Sell
983
-53
-5% -$6.88K ﹤0.01% 452
2023
Q1
$136K Buy
1,036
+6
+0.6% +$785 ﹤0.01% 667
2022
Q4
$120K Buy
1,030
+14
+1% +$1.81K ﹤0.01% 606
2022
Q3
$119K Sell
1,016
-140
-12% -$17.4K ﹤0.01% 469
2022
Q2
$151K Buy
+1,156
New +$137K ﹤0.01% 382

Other funds holding IBB

Blue Trust's IBB Position: Q3 2026 in Review

Blue Trust increased its iShares Biotechnology ETF (IBB) stake by 5.7% in Q3 2026, buying an estimated $11.2K and bringing the position to 1,037 shares worth $218K. The position accounts for ﹤0.01% of the portfolio, ranked #724.

Blue Trust first reported a position in IBB in Q2 2022 and has held it in 18 quarters since. 920 funds tracked by Wall St. Rank hold IBB as of Q3 2026.

  • Blue Trust held 1,037 shares of iShares Biotechnology ETF worth $218K as of Q3 2026.
  • Blue Trust bought 56 iShares Biotechnology ETF shares in Q3 2026, an estimated $11.2K.
  • iShares Biotechnology ETF made up ﹤0.01% of Blue Trust's portfolio in Q3 2026, its #724 holding.
  • Blue Trust first reported a position in iShares Biotechnology ETF in Q2 2022 and has held it in 18 quarters since.
  • 920 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q3 2026.

Based on Blue Trust's 13F filing for Q3 2026, filed 15 Oct 2026.